Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Paul Offit

Peds Vaccinology · CHOP

View

Dr. Guliz Erdem

Peds ID · Ut health Houston

View

Dr. Philip Schauer

Bariatric Surgery · PBRC

View

Dr. Justin Hovey, FAAP, FACP, DABOM

Obesity Medicine · Noland Hospital Dothan II

View

Dr. Kimberly Gudzune

Obesity Medicine · JHU

View

Dr. Richard Dutton

General Anesthesiology · UMSOM

View

Dr. Sarah Ro

Obesity Medicine · UNC Health Care

View

Dr. Rebecca Andrews

Primary Care · UCHC

View

Dr. Jed Wolpaw

General Anesthesiology · Johns Hopkins

View

Dr. Matt Sherrer

Perioperative Med · UAB

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms

    Overview

    Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022).

    Jun 27, 2024DOI: 10.1093/cid/ciac724Journal ArticleCID

    Written by: Adarsh BhimrajRebecca L MorganAmy Hirsch ShumakerLindsey R BadenVincent Chi-Chung ChengKathryn M EdwardsJason C GallagherRajesh T GandhiWilliam J MullerMari M NakamuraJohn C O'HoroRobert W ShaferShmuel ShohamM Hassan MuradReem A MustafaShahnaz SultanYngve Falck-Ytter

    Find these authors on Roon

    WM
    Dr. William Muller
    Peds Transplant ID · Lurie Children's Hospital

    Summary

    There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence from trials. The objective was to develop evidence-based, rapid, living guidelines intended to support patients, clinicians, and other healthcare professionals in their decisions about treatment and management of patients with COVID-19. In March 2020, the Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise to regularly review the evidence and make recommendations about the treatment and management of persons with COVID-19. The process used a living guideline approach and followed a rapid recommendation development checklist. The panel prioritized questions and outcomes. A systematic review of the peer-reviewed and grey literature was conducted at regular intervals. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. Based on the most recent search conducted on 31 May 2022, the IDSA guideline panel has made 32 recommendations for the treatment and management of the following groups/populations: pre- and postexposure prophylaxis, ambulatory with mild-to-moderate disease, and hospitalized with mild-to-moderate, severe but not critical, and critical disease. As these are living guidelines, the most recent recommendations can be found online at: https://idsociety.org/COVID19guidelines. At the inception of its work, the panel has expressed the overarching goal that patients be recruited into ongoing trials. Since then, many trials were conducted that provided much-needed evidence for COVID-19 therapies. There still remain many unanswered questions as the pandemic evolved, which we hope future trials can answer.
    WMDr. William Muller

    Dr. William Muller

    Pediatric Infectious Diseases · Pediatric Transplant Infectious Disease
    Lurie Children's Hospital
    williammuller